Diversity in Functional Organization of Class I and Class II Biotin Protein Ligase

Sudha Purushothaman¹, Karthikeyan Annamalai¹, Anil K. Tyagi³, Avadhesha Surolia¹,²

¹Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India, ²National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India, ³Department of Biochemistry, University of Delhi South Campus, New Delhi, India

Abstract

The cell envelope of Mycobacterium tuberculosis (M.tuberculosis) is composed of a variety of lipids including mycolic acids, sulfolipids, lipoproteinmannans, etc., which impart rigidity crucial for its survival and pathogenesis. Acyl-CoA carboxylase (ACC) provides malonyl-CoA and methylmalonyl-CoA, committed precursors for fatty acid and essential for mycolic acid synthesis respectively. Biotin Protein Ligase (BPL/BirA) activates apo-biotin carboxyl carrier protein (BCCP) by biotinylating it to an active holo-BCCP. A minimal peptide (Schatz), an efficient substrate for Escherichia coli BirA, failed to serve as substrate for M. tuberculosis Biotin Protein Ligase (MtBPL). MtBPL specifically biotinylates homologous BCCP domain, MtBCCP87, but not EcBCCP87. This is a unique feature of MtBPL as EcBirA lacks such a stringent substrate specificity. This feature is also reflected in self/promiscuous biotinylation by MtBPL. The N-terminus/HTH domain of EcBirA has the self-biotinatable lysine residue that is inhibited in the presence of Schatz peptide, a peptide designed to act as a universal acceptor for EcBirA. This suggests that when biotin is limiting, EcBirA preferentially catalyzes, biotinylation of BCCP over self-biotinylation. R118G mutant of EcBirA showed enhanced self and promiscuous biotinylation but its homologue, R69A MtBPL did not exhibit these properties. The catalytic domain of MtBPL was characterized further by limited proteolysis. Holo-MtBPL is protected from proteolysis by biotinyl-5'AMP, an intermediate of MtBPL catalyzed reaction. In contrast, apo-MtBPL is completely digested by trypsin within 20 min of co-incubation. Substrate selectivity and inability to promote self-biotinylation are exquisite features of MtBPL and are a consequence of the unique molecular mechanism of an enzyme adapted for the high turnover of fatty acid biosynthesis.

Introduction

Mycobacterium tuberculosis has become resistant to most drugs. The cell wall, composed of almost 60% lipids that are long chain, branched fatty acids, is highly hydrophobic and hence refractory to several components of human defense system. It also provides an effective permeability barrier against several anti-mycobacterial agents [1–3]. The rich diversity of lipids present in M. tuberculosis is reflected at the genomic level by a large repertoire of genes for lipid biosynthesis. M. tuberculosis, for example, has ~300 enzymes involved in lipid synthesis while E. coli has only about 50 [4–7].

Biotin-dependent enzymes are involved in carboxylation and decarboxylation reactions. Acyl-CoA carboxylases (ACC) catalyze biotin-dependent carboxylation of nascent molecules such as acetyl-CoA, propionyl-CoA etc. These carboxylases are multi-subunit, multi-domain proteins consisting of α and β subunits. M. tuberculosis has three copies of α-subunits which are composed of a N-terminus biotin carboxylase (BC) and a C-terminus biotin carboxyl carrier protein (BCCP). All biotinyl domains so far reported have a target lysine at ~35th residue from C-terminus for biotinylation [8]. Hence, a protein composed of C-terminus 87 amino acids of ace is an efficient substrate for Biotin Protein ligase [8]. Biotinylation of BCCP is catalyzed by Biotin Protein Ligase (BPL) which promotes an amide linkage between the carboxyl group of biotin and the ε-amino group of a specific lysine residue nestled within a conserved ‘AMKM’ sequence of BCCP. Biotinylation converts inactive apo-BCCP to functional holo-BCCP that participates in the transcarboxylation reaction [9,10]. Thus, BCCP has two functions - mechanistic by serving as carboxyl carrier in overall carboxylation reaction and structural, by swaying carboxybiotin to the carboxyl transferase component of ACC. BC carboxylates the ureido nitrogen atom of biotin covalently bound to BCCP which moves {CO2}-biotin to the active site of carboxyl transferase (CT), for the transfer of a carboxyl group to acetyl or propionyl CoA [11,12]. The entire sequence of carboxylation reaction and the key role played by BCCP is schematically represented in Figure 1.

In spite of a highly conserved function, BCCPs display unique features for their respective biotinylating enzymes. In solution, apo-BCCP (E. coli, Pyrococcus horikoshii) is a flattened β-barrel structure comprising of two four-stranded β sheets [12,13]. In most BCCPs, the biotinatable lysine is nestled within the conserved tetrapeptide ‘AMKM’ sequence in an exposed β-turn of BCCP domain. However, in Sulfolobus tokodaii, the canonical lysine residue within the sequence ‘AMKS’ was not biotinylated by E. coli BirA.
[14,15]. In *Aquifex aeolicus* (*AaBPL*), the target lysine is within the ‘ALKV’ sequence [16]. BCCP of *M. tuberculosis* (*MtBCCP*) is part of a multi-domain enzyme, biotin carboxylase and this probably alters its dynamics with the cognate enzyme, *M*. *BirA*. *MtBirA* can biotinylate BCCPs of other species. *MtbBPL* belongs to class I BPLs which lack a DNA binding domain at their N-termini unlike the class II BPLs (e.g. *E. coli BirA*) hence are devoid of repressor function exhibited by class II BPLs [17–19]. Our previous study showed that the two enzymes differ in several ways from structural organization to ligand interactions [20]. *EcbirA* can biotinylate BCCPs of other species. *MtbBPL* as shown in this study, in contrast, to *EcbirA* exhibits exquisite substrate specificity. The differences in their activities are correlated here with their intrinsic metabolic functions.

### Results

#### Protein purification

It has been reported that the C-terminus domain of BCCP (apo-BCCP87), does not self-associate and was a good substrate for biotinylation reaction [11,12]. Hence *EcbirA* and *MtBirA* expressed in pET28a were used for avidin blot assays. The BCCP was purified by Ni-NTA column chromatography. The apo form was separated from the holo form using a Mono Q column pre-equilibrated with 10 mM Tris-HCl buffer (pH 8.0) prior to the elution of the protein with a salt gradient (0–100% 10 mM Tris-HCl pH 8.0, 1 M NaCl). Fractions containing apo-BCCP were checked on avidin blot, pooled and dialyzed against 10 mM Tris-HCl pH 8.0, 2.5 mM MgCl2 (standard buffer). Thus 95% of the purified *MtBirA* was found to be in their apo form. The biotinylation reaction was found to be dependent on Mg2+, ATP and biotin. BCCP and BPL were dialyzed against the standard buffer prior to use.

For self-biotinylation assays, BL21 containing *EcbirA* construct was grown in M9 media supplemented with 2% glucose for 5 h and induced for 3 h to prevent endogenous self-biotinylation. The eluted protein was dialyzed, concentrated and dialyzed against standard buffer.

#### Domain architecture of Biotin protein ligase

The domain structure of *MtbBPL* and *EcbirA* was obtained from pfam (Figure 2) [21]. The different domains of BPL are:

- **HTH.** The helix-turn helix domain.
- **BPL _LipA_ _LipB._** This family includes biotin protein ligase, lipoate-protein ligase A and B.
- **BPL C.** The C-terminus domain has a SH3-like barrel fold, the function of which is unknown. BPL family is a member of clan **TRB** (Transcriptional repressor beta-barrel domain). This beta-barrel domain is found at the C-terminus of a variety of transcriptional repressor proteins. As shown in the Figure 2, Biotin Protein Ligase of *M. tuberculosis* lacks the N-terminus HTH domain and hence does not function as a repressor.

#### Substrate specificity of *MtBPL*

The molecular behavior of *MtbBPL* and *EcbirA* are different due to the presence of an additional repressor function in *EcbirA*. It has been documented that *EcbirA* biotinylates BCCPs from other species except the one from *S. tokodii* [15]. In fact, *EcbirA* efficiently biotinylated the synthetic biotinatable minimal peptide of sequence ‘GLNDIFEAQKIEWH’ (Schatz peptide) which is known to be a good substrate for BPLs (Figure 3b). In contrast, *MtbBPL* failed to biotinylate Schatz peptide (Figure 3a). Subsequently, we investigated the ability of *MtbBPL* and *EcbirA* to cross biotinylate *MtBirA* and *MtBCCP* and *MtbBCCP* (5 μM) were incubated with 500 μM biotin, 3 mM ATP, 100 nM *EcbirA* or *MtbBPL* for 30 min at 37° C. *EcbirA* efficiently biotinylated both the BCCPs but *MtbBPL* selectively biotinylated its cognate substrate (Δ*MtBCCP*87) alone and failed to biotinylate *MtbBCCP*87 (Figure 3c).

#### Self-biotinylation of *EcbirA*

When substrate specificity of BPLs was explored, at higher enzyme concentration, a protein with molecular weight corresponding to *EcbirA* was detected on avidin blot indicating that *EcbirA* undergoes self-biotinylation. This is consistent with the report of Choi-Rhee *et al.* [22]. Therefore, we investigated if *MtbBPL* was capable of self-biotinylation like its counterpart in *E. coli*. *MtbBPL* or *EcbirA* (250–2000 nM) were subjected to

---

*Figure 1. Schematic outline of the functional cycle of the BCCP subunit of acetyl CoA carboxylase. The BCCP is involved in three homologous protein-protein interactions with the Biotin Protein Ligase (BPL), Biotin carboxylase (BC) and Carboxyl transferase (CT). doi:10.1371/journal.pone.0016850.g001*
biotinylation reaction for 1 h in the absence of BCCP. The biotinylation mixture was resolved on 12% SDS-PAGE, transferred onto nitrocellulose membrane and detected by streptavidin HRP. The control, EcBirA was self-biotinylated at concentration as low as 500 nM (Fig S1). In contrast, MtBPL did not undergo self-biotinylation even at 2000 nM (Lane 2–6, Fig S1). Hence, our focus was to study the implications of the lack of self-biotinylation in MtBPL.

EcBirA has an additional N-terminus HTH domain which contributes to the repressor function of the protein (Figure 2). Earlier reports suggested that truncated EcBirA (D1–34) was enzymatically active but did not undergo self-biotinylation [22]. This suggested that the N-terminus probably carries the biotinable residues. So, the N-terminus domain (1–65 amino acids) was independently cloned in pGEX4T-1. The fused GST-HTH domain of EcBirA (pGEN1) was subjected to biotinylation using enzymatic concentration of 100 nM MtBPL/EcBirA. The fused protein was biotinylated by full length EcBirA (Figure 4). The control GST protein was not biotinylated by EcBirA. This confirms that the self-biotinylatable lysine is within the N-terminus/HTH domain of EcBirA. It also suggests that the catalytic and self-biotinatable domain require no physical contiguity for the covalent modification. Hence, this construct was used to investigate if the lack of self-biotinylation in MtBPL was because (i) MtBPL lacks the N-terminus domain or (ii) the enzyme was deficient in promoting self-biotinylation. MtBPL failed to biotinylate HTH–GST fusion protein (pGEN1) but EcBirA efficiently biotinylated the fusion protein. This suggests that the mere presence of self-biotinatable residue does not confer MtBPL an ability to self-biotinylate. Furthermore, non-specific proteins such as BSA was biotinylated by EcBirA but not by MtBPL (Fig S2). This clearly reiterates that MtBPL does not catalyze indiscriminate biotinylation. Thus, the inability of MtBPL to undergo self-biotinylation could be attributed to two factors: absence of an HTH domain and a stringent catalytic specificity of the enzyme. (Figure 4).

Competitive inhibition of self-biotinylation by Schatz peptide

The intermediate molecule, bio-5’AMP, appears to play a central role in several processes. We investigated if bio-5’AMP was preferentially used for self-biotinylation of HTH domain or biotinylation of biotin acceptor molecule. For this, self-biotinylation of EcBirA was performed in the presence of saturated concentration of Schatz peptide or BCCP [5 μM]. EcBirA failed to undergo self-biotinylation or promote biotinylation of heterologous HTH (pGEN1) domain in the presence of excess biotin acceptor molecule such as Schatz peptide (Figure 5). Indeed, the bio-5’AMP synthesized was used for biotinylation of biotin acceptor molecules, Schatz peptide and BCCP, rather than for self-biotinylation. Also to confirm that the covalently modified self-biotinylated EcBirA was dialyzed to remove unbound biotin and ATP and then incubated with Schatz peptide. The covalently modified self-biotinylated EcBirA failed to endogenously biotinylate Schatz peptide. However, the addition of biotin and ATP to previously self-biotinylated EcBirA led to the conversion of apo-Schatz peptide to biotinylated form (Fig S3).

Mutation analysis

Choi-Rhee et al have shown that the affinity of R118G mutant of EcBirA for biotin decreased by ~100 fold and the self-biotinylation increased several fold [22]. However, for the homologous R69A mutant of MtBPL the binding constant for biotin was nearly the same as that observed for the wild type protein (data not shown). Also, the R69A mutant of MtBPL did not undergo self-biotinylation (Lane 12, Figure S1). This highlights the differences in the structural and functional organization of EcBirA and MtBPL.

Limited proteolysis

Purified MtBPL was subjected to proteolytic digestion with protease trypsin for 20 min and the products were analyzed on
12% SDS PAGE in order to define the domain boundaries within the enzyme. The enzyme was subjected to limited proteolysis in the presence and absence of biotin and MgATP. Trypsin generated two fragments, one of about ~8.2 kDa and the other of ~21 kDa as determined by N-terminus sequencing and SDS-PAGE (Figure 6a, b). The ~8.2 kDa has an N terminus His-tag which was identified by its reactivity with the anti-His antibody. Also, the ~8.2 kDa fragment was susceptible to further proteolysis. The N-terminus sequencing of these products revealed the cleavage occurred between Arg-72 and Gly-73 for trypsin. Since these cleavage points are located around the conserved biotin binding site (GRGRHGR), MtBPL was subjected to proteolytic digestion in the presence of saturating amounts of the substrates, biotin and ATP as well as both of them together. Incubation with ATP did not alter the cleavage by trypsin with 83% of the protein being digested. Incubation with biotin did reduce the proteolysis with nearly 40% of the protein intact. However, incubation of MtBPL with both biotin and ATP completely protected nearly all the protein from proteolytic digestion by trypsin. This was also observed when the protein was pre-incubated with chemically synthesized bio-5’-AMP. In fact the intermediate molecule, biotinyl-5’-AMP protected the protein from proteolytic digestion for over 24 h. Thus, when biotin and ATP were pre-incubated with the enzyme, biotinyl-5’-AMP was synthesized and this intermediate molecule protected the protein from proteolysis by binding to the active site of the enzyme. MtBPL was incubated with saturating amounts of biotin and non-hydrolyzable ATP analogue AMPpNpp and then treated with trypsin. The protein showed reduced protection against the protease as the non-hydrolyzable ATP analog failed to synthesize biotinyl-5’-AMP. Taken together, these results suggest that the binding of the substrates and/or the formation of the intermediate, biotinyl-5’-AMP, protects BPL from protease cleavage.
Discussion

Acetyl CoA carboxylase of *M. tuberculosis* belongs to the class of heteromeric ACCases which are multi-domain, multi-subunit enzyme. The subunit assembly of *accA3* and *accD6* complex in association with ε- subunits has been studied in detail [8]. The BCCP domain of heavier α (*accA*) subunit interacts with three distinct heterologous proteins; BCCP-BC, BCCP-CT and BCCP-BPL. Considering the complexity of the cell wall of *M. tuberculosis*, it is not surprising that the pathogen has so many of these enzymes with biotinyl domains.

BCCP is a key player in carboxylation and transcarboxylation reactions which shuttle carboxyl group from BC to CT of ACC to

Figure 4. Biotinylation of GST-HTH domain by EcBirA or MbPL. 5 μM fusion protein was incubated with 500 μM biotin, 3 mM ATP, 100 nM EcBirA in standard buffer for 1 h. The sample was then resolved on 10% SDS-PAGE and transferred to nitrocellulose membrane and the biotinylated protein was detected by streptavidin HRP and H₂O₂. (1) marker; (2) GST-HTH fusion protein (pGEN1)+100 nM EcBirA; (3) GST-HTH fusion protein (pGEN1)+50 nM EcBirA (4) GST – HTH fusion protein+100 nM MtBPL.
doi:10.1371/journal.pone.0016850.g004

Figure 5. Competitive inhibition of GST-HTH protein and EcBirA in the presence of excess amount of Schatz peptide. GST-HTH (5 μM) was incubated with biotin, ATP and 100 nM EcBirA or EcBirA (2 μM) was incubated with biotin, ATP in the presence/absence of Schatz peptide for 1 h at 37°C. The biotinylated proteins were detected by streptavidin HRP. (1) Protein marker; (2) GST-HTH protein; (3) GST-HTH+Schatz peptide; (4) EcBirA; (5) EcBirA+Schatz peptide.
doi:10.1371/journal.pone.0016850.g005
initiate fatty acid elongation. As a prelude to carboxylation of biotin to transcarboxylation of acyl-CoA, BPLs must selectively interact with BCCP. Relating structure to function of a protein that participates in multiple interactions is fraught with difficulties [23,24]. From the crystal structures of P8BCCP and EbBCCP, it was evident that target lysine is located at the type I β-turn [11,25]. In most post-translational modifications, the primary structure surrounding target residue is critical. But from the structural organization to interact with their homologous enzyme(s) [13]. The BCCP domains from different species have varied relatively large conformational changes to accommodate BCCP crucial cysteine residue. The C-terminus of BPL undergoes of holo- tifs and are probably part of the active site. The invariant lysine within the KIAGLEV plays an essential catalytic role during synthesis of bio-5’AMP and the KWPN plays the motif with streptavidin. Thus, the lack of self-biotinylation in MBPL is due to the absence of a biotinylatable lysine residue. The two lysine residues of MBPL are within the conserved ‘KWPND’ and ‘KIAGLEV’ motifs and are probably part of the active site. The invariant lysine within the KIAGLEV plays an essential catalytic role during synthesis of bio-5’AMP and the KWPN domain is currently under investigation in our laboratory. In biotinylation of BCCP, an electrostatic interaction between negative phosphate group of bio-5’AMP and positively charged lysine of BCCP are key elements. The uncharged lysine in BCCP is deprotonated by
aspartate residues of *EcBirA* which promotes a nucleophilic attack on the electrophilic carbonyl group of bio-5'-AMP leading to covalent modification [27]. It is possible that a similar mechanism promotes self-biotinylation of HTH domain of *EcBirA*. However, the self-biotinylatable residues in BPLs may not have sufficient accessibility and reactivity for accepting biotin and hence require longer incubation which perhaps accounts for a lag period of 1 h. 

Intramolecular interaction of BPL and BCCP probably allows for a snug fit which in turn promotes a fast and efficient covalent modification of the acceptor target lysine in BCCPs. On the other hand intramolecular folding of BPL initiated by bio-5'-AMP may impart steric hindrance which probably restrains orientation of the adenylate towards the self-biotinylable lysine.

Intramolecular folding in *EcBirA* enables deprotonation of self-biotinylatable/promiscuous biotinylatable lysine residue leading to its covalent modification. However, the transition state of *MbBPL* probably selects the specific acceptor molecule which in turn explains its stringent specificity for its cognate BCCP. Studies reported show that *MbBPL* differs from *EcBirA* and probably other BPLs in many additional ways; (a) *MbBPL* is a monomer in both its apo and holo forms and has relatively lower affinity for biotin and bio-5'-AMP (b) In *EcBirA*, self-biotinylation was enhanced in R118G mutant which releases bio-5'-AMP leading to increased self-biotinylation of the mutant protein. The R69A mutant of *MbBPL* failed to undergo self-biotinylation suggesting that the proclivity of the enzyme for biotinylation was different from that of *EcBirA*. The R69A *MbBPL* has similar affinity for biotin as that of wild type in contrast to R118G *EcBirA* which exhibited reduced affinity for biotin. Self-biotinylation of *EcBirA* occurs only in the absence of a biotin acceptor molecule. This is of relevance to the repressor function of *EcBirA* which occurs only in the absence of the enzyme to meet the demands of cell wall synthesis. As this is a rate limiting step, the enzyme avoids self/promiscuous biotinylation to conserve the scarce co-factor whose biosynthesis itself is an extremely slow process. This is due to the low turn over of *BioB* and its degradation under low iron concentration [32,33]. Additionally, uncoupling biotinylation and repressor functions would favor fatty acid biosynthesis [34]. Hence, the mycobacterium cell probably reserves all the biotin at its disposal for biotinylation of *act* to meet the demands of cell wall biosynthesis (Figure 7a).

**Proposed rationale for the diverse functional organization of BPLs**

*MbBPL*. We reported earlier that *MbBPL* in spite of lower affinity for biotin had *Km* similar to that of *EcBirA* [20]. Deletion of N-term domain of *EcBirA* decreases binding affinity of the enzyme by ~100 fold [29]. This suggests that higher binding constant of *EcBirA* for biotin may be directed towards covalent modification of HTH domain. In *MbBPL*, fatty acid synthesis plays central role for its cell wall synthesis. As this is a rate limiting step, the enzyme avoids self/promiscuous biotinylation to conserve biotin, a scarce co-factor whose biosynthesis itself is an extremely slow process. This is due to the low turn over of *BioB* and its degradation under low iron concentration [32,33]. Additionally, uncoupling biotinylation and repressor functions would favor fatty acid biosynthesis [34]. Hence, the mycobacterium cell probably reserves all the biotin at its disposal for biotinylation of *act* to meet the demands of cell wall biosynthesis (Figure 7a).

**E. coli**. The intermediate molecule, bio-5'-AMP can be utilized for any of the three function: biotinylation of BCCP, self-biotinylation or as a co-repressor depending on the cellular demands (Figure 7b).

![Figure 7. A schematic illustration proposing the mechanism of biotin utilization and their physiological significance.](https://doi.org/10.1371/journal.pone.0016850.g007)
1) At high BCCP concentration, low bio-5’AMP [+] mediates biotinylation of biotin acceptor molecule. 

2) At low BCCP concentration and moderate bio-5’AMP [++] , when the cell does not require biotin for biotinylation reaction, bio-5’AMP [++] probably needs to functions as a co-repressor of biotin biosynthetic pathway and repress synthesis of biotin. However, this would be favored only if E.coli does not require immediate fatty acid biosynthesis to operate. But the bacterium during the transition, probably requires additional time to decide whether it wants to block the biotin biosynthetic pathway. Under such a situation, in the absence of BCCP, the bio-5’AMP is directed towards self-biotinylation. This prevents the bio-5’AMP to be utilized as a co-repressor of biotin biosynthetic pathway. The self-biotinylated EcBirA is enzymatically active to participate in the biotinylation of BCCP. This is primarily because transcription activation or repression has to be modulated according to the cellular requirements [34]. 

3) However, when the concentration of bio-5’AMP [+++] is abundant it functions as a co-repressor and shuts the biotin biosynthetic pathway.

Our results support the proposed hypothesis as self-biotinylation is competitively inhibited by biotin acceptor molecule which is increased in the presence of operator sequence of biotin biosynthetic pathway [18]. The preferred order of bio-5’AMP utilization by EcBirA is: 

Biotinylation > Self-biotinylation > Co-repression 

Thus the evolutionary process has devised different mechanism in EcBirA and MbpB commensurate with the functional requirement of the organism. The birA repressor function is separated from enzyme function in MbpB as lipid biosynthesis is very critical in M. tuberculosis. As the repressor function is not coupled to the enzyme function the enzyme does not promote self-biotinylation. However, in E. coli during the evolutionary process, the enzyme has probably compromised its substrate specificity and has also acquired self as well as promiscuous biotinylation.

Yao et al [35,36] suggested that though functionality and overall folding of biotinyl domains are conserved through evolution, the detailed structures of BPL-BCCP binding interface may vary among different species. The substrate stringency of MbpB may add to its ability to regulate the acyl CoA carboxylases in M. tuberculosis.

In conclusion, our studies with MbpB show that biotinylation process is not dependent merely on recognition of a target residue but involves an intricate play between the biotin acceptor (BCCP) and its cognate ligase. MbpB plays an active role in substrate selection which occurs by an integration of an intricate series of events involved in BPL-BCCP interaction and biotin demands of the cell. The stringency exhibited by MbpB makes it a suitable target for the development of anti-mycobacterials and vaccine.

**Materials and Methods**

**Protein methods**

*M. tuberculosis* BPL (Rv3279c) was cloned into pET28a at NdeI/HindIII sites and the protein purified as described by Purushothaman et al [20]. Mutant R69A was generated by site-directed mutagenesis and cloned into NdeI/HindIII sites and sequence analyzed. The procedure used for the purification of the mutant protein was identical to that of its wild type counter-part wild type [20]. EcBirA and (Δ1–65) EcBirA. *M. tuberculosis* has three acetyl-/propionyl coenzymeA carboxylase α subunit *accA* (Rv2501c), *accA2* (Rv0973c), *accA3* (Rv3285c), and a putative acetyl CoA carboxylase subunit BCCP *TBP*. (Rv3221c) and six β subunit, *acdB* genes [7,8]. All biotinyl domains so far reported have target lysine at -53th residue from C-terminus for biotinylation. Hence, we cloned the C-terminus 87 amino acid residues of *accA* as the substrate for MbpB, MBCCP87 and EcBCCP87 were cloned into pET28a. The PCR primers used for amplification reaction are listed in Table 1. For self-biotinylation studies, BL21 expressing EcBirA was grown in M9 minimal media supplemented with 2% glucose for 4 h and then induced with 100 μM IPTG for 3 h. This was carried out to prevent autologous self-biotinylation.

**Schatz minimal peptide**

A minimal peptide, Schatz peptide, which is efficiently biotinylated by EcBirA GLNDFEAQKIEWH (Genscript, USA) [37], was used for some of the experiments (37). The peptide (5μM) was incubated with 100 nM of EcBirA/MbpB, biotin (500 μM), ATP (3 mM) for 1 h at 37°C in standard buffer and the biotinylation was detected by MALDI-TOF.

**Matrix-assisted laser desorption time of flight mass spectrometry**

The molecular weight of Schatz and holo-Schatz peptides were determined by MALDI-TOF MS using a Ultraflex TOF/TOF (Bruker Daltons Germany) equipped with a N2 Laser, 337 nm, 50 Hz operating in the 25 kV reflector mode. Samples were dialyzed against water and 1 μl of sample was mixed with equal volume of matrix solution on a stainless steel plate and air-dried prior to analysis. The matrix solution used was α-cyano-4-hydroxy-cinnamic acid in 50% acetonitrile, 0.1% (v/v) trifluoro-acetic acid. Mixture of appropriate standards was used for calibration and Schatz and holo-Schatz peptide analytes were analyzed as described above and calibration was performed using the known protonated molecular ion (MH+).

**Fast Protein Liquid Chromatography**

A reaction mixture of MbpB (20 μM), biotin (500 μM), ATP (3 mM), MgCl2 (2.5 mM), and MBCCP87 (20 μM) were incubated for 30 min at 37°C and then 200 μl of the reaction mixture was loaded onto Superdex S200 (GE, Healthcare) and analyzed.

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBCCP87 fwd</td>
<td>5’-GGAATTCCTTATGCGACCCTGGCGGAGGCCGAGGA-3’</td>
</tr>
<tr>
<td>MBCCP87 rev</td>
<td>5’-CCCGAGCTTGCATGAGCCCGAGCGGGGAGCGG-3’</td>
</tr>
<tr>
<td>EcBCCP87 fwd</td>
<td>5’-GGAATTCATGAGCCCGAGCGGGGAGCGG-3’</td>
</tr>
<tr>
<td>EcBCCP87 rev</td>
<td>5’-CCCGAGCTTGCATGAGCCCGAGCGGGGAGCGG-3’</td>
</tr>
<tr>
<td>EcBirA fwd</td>
<td>5’-GGAATTCCTTATGCGACCCTGGCGGAGGCCGAGGA-3’</td>
</tr>
<tr>
<td>EcBirA rev</td>
<td>5’-CCCGAGCTTGCATGAGCCCGAGCGGGGAGCGG-3’</td>
</tr>
<tr>
<td>TrfEcBirA fwd</td>
<td>5’-GGAATTCCTTATGCGACCCTGGCGGAGGCCGAGGA-3’</td>
</tr>
<tr>
<td>TrfEcBirA rev</td>
<td>5’-CCCGAGCTTGCATGAGCCCGAGCGGGGAGCGG-3’</td>
</tr>
<tr>
<td>R69A MbpB fwd</td>
<td>5’-ATCGCGGGAGCAGTCAGCCCGTGGCGGGGAGCGG-3’</td>
</tr>
<tr>
<td>R69A MbpB rev</td>
<td>5’-TGGGGAGCAGTCAGCGGGGAGCGG-3’</td>
</tr>
</tbody>
</table>

**Table 1. List of primers used.**

doi:10.1371/journal.pone.0016850.001
eluted at a flow rate of 0.2 ml/min and the eluted samples were monitored at 280 nm. The gel filtration column was calibrated with alcohol dehydrogenase, BSA, ovalbumin, carbonic anhydrase and chymotrypsin and lysozyme. Also, purified MBCCP$_{350}$ was loaded on to the column to determine the oligomeric status of apo-MBCCP$_{350}$.

**Biotinylation assay**

Biotin acceptor molecule (BCCP or Schacht peptide) were incubated with 500 μM biotin, 3 mM ATP, 2.5 mM MgCl$_2$ and 100 nM MBPL or EcBirA in standard buffer for 1 h at 37°C. The biotylated proteins were detected by avidin blot and mass spectrometry.

**Self-biotinylation reaction**

To determine self-biotinylation, different concentration of EcBirA/MBPL were incubated with 3 mM (ATP), biotin (500 μM) in standard buffer for 1 h at 37°C. The biotinylated protein was then detected by streptavidin blot.

**Avidin blot**

Biotinylated proteins were resolved on 10% SDS-PAGE and transferred to nitrocellulose membranes. The non-specific sites were blocked with 5% skim milk in Phosphate buffered saline +0.1% Tween20, pH-7.4, (PBS-T) and incubated with streptavidin-HRP (Sigma) at 1:2000 dilution for 1 h at room temperature. The membrane was washed 5× with PBS-T and 2× with PBS and detected by 3-amino-9- ethylcarbazole (AEC)/H$_2$O$_2$.

**Limited proteolysis**

MBPL (5 μM) was incubated with trypsin (1:200) dilution and incubated at 37°C for 20 min. The enzyme was pre-incubated with biotin (500 μM) and ATP (3 mM) at 37°C for 30 min prior to trypsin digestion. After protease treatment, the sample solubilizing dye was added to the protein, boiled and loaded on to a 10% SDS-PAGE. The resolved proteins were scanned and percentage of proteolysis determined. The digested product was sequenced from the N-terminus on an Applied Biosystems Precise 491 CLC Protein Sequencer.

**Supporting Information**

**Figure S1** Self-biotinylation of EcBirA, MBPL and R69A MBPL mutant by avidin blot. MBPL/EcBirA (250–2000 nM)/R69A (2000 nM) were incubated with 3 mM ATP and 500 μM biotin in standard buffer (10 mM Tris-HCl pH-8.0, 50 mM KCl, 2.5 mM MgCl$_2$) for 1 h at 37°C. The reaction mixture was resolved on a 10% SDS PAGE and transferred to nitrocellulose membrane. The membrane was then incubated with streptavidin HRP for 1 h at room temperature and developed with AEC/H$_2$O$_2$ (1) marker; (2–6) 250–2000 nM of MBPL; (7–11) 250–2000 nM of EcBirA; (12) 2000 nM of R69A MBPL. See also Figure S2.

**Figure S2.** Promiscuous biotinylation property of EcBirA and MBPL by avidin blot. BSA (2 μM) were incubated with 3 mM ATP, 500 μM biotin and 100 nM BPL in standard buffer (10 mM Tris-HCl pH-8.0, 50 mM KCl, 2.5 mM MgCl$_2$) for 2 h at 37°C. The reaction mixture was then resolved on a 10% SDS PAGE and transferred to nitrocellulose membrane. The membrane was then incubated with streptavidin HRP for 1 h at room temperature and developed with AEC/H$_2$O$_2$ (1) marker (2) BSA+400 nM MBPL; (3–5) BSA+200, 300, 400 nM of EcBirA.

**Figure S3** Catalytic activity of self-biotinylated EcBirA. Self-biotinylated EcBirA was dialyzed to remove free biotin/ATP. The enzyme was then used to transfer biotin to Schacht peptide in the absence or presence of endogenous biotin and ATP. (a) Mass spectrum of Schacht peptide incubated with self-biotinylated EcBirA in standard buffer. (b) Mass spectrum of Schacht peptide incubated with self-biotinylated EcBirA incubated with endogenous 500 μM biotin, 3 mM ATP and in standard buffer.

**Author Contributions**

Conceived and designed the experiments: SP AS. Performed the experiments: SP AT. Analyzed the data: SP AS AT. Contributed reagents/materials/analysis tools: AS. Wrote the manuscript: SP AS.

**References**


